FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204194265> ?p ?o ?g. }

• W3204194265 endingPage "6690" @default.
• W3204194265 startingPage "6682" @default.
• W3204194265 abstract "Serum IgG anti-Vi titers attained by 327 children 6-23 months of age immunized with Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®), of whom 193/327 received a booster dose 2 years post-primary vaccination, were previously reported.Anti-Vi IgG in boosted and unboosted children 3, 5, and 7 years post-primary immunization were monitored using three different enzyme-linked immunosorbent assays (ELISAs): Vacczyme™ kit ELISA (all specimens); Szu ELISA (all specimens), and National Institute of Biological Standards NIBSC ELISA (subset). Endpoints analyzed included: persisting seroconversion (titer remaining ≥ 4-fold above baseline), geometric mean titer (GMT), geometric mean-fold rise post-vaccination, and percent exhibiting putative protective anti-Vi level (≥2 µgSzu/ml) using Szu method and National Institutes of Health IgG reference standard. In assessing the persistence of elevated anti-Vi titers stimulated by Typbar-TCV®, four subgroups were compared based on whether or not the initially enrolled children were boosted on day 720 and whether they provided serum on all key timepoints, or if they missed one or more timepoints: i) Among boosted participants, an All Specimens Cohort (ASC) comprised 86 children who provided sera on days 42, 720 (booster), 762 (42 days post-booster), 1095, 1825 and 2555, to define kinetics of the Vi antibody response in a fully compliant cohort of boosted children monitored over seven years; ii) Among non-boosted subjects, a compliant All Specimens Cohort of 25 children provided sera on days 0, 42, 720, 1095, 1825, and 2555; iii) Among boosted children, an Any Available Specimen (AAS) subgroup consisted of boosted children who provided sera on days 0, 42, and 720 days and also on one or more of days 762, 1095, 1825, or 2555 but not on all those time points; iv) Among the non-boosted subjects, there was also an Any Available Specimen subgroup of 47 children who provided sera on days 0 and 42, of whom 41 subsequently contributed sera on one or more of days 1095, 1825 and 2555.Vacczyme™ GMTs among boosted ASC children (N = 86) increased significantly on day 762, and remained 32-fold, 14-fold, and 10-fold over baseline at 3, 5 and 7 years; among unboosted ASC children (N = 25), GMTs remained 21-fold, 8-fold and 5-fold over baseline, respectively. Post-primary vaccination, 72% and 44% of unboosted ASC subjects (N = 25) exhibited persisting seroconversion by Vacczyme™ at 5 and 7 years, respectively; the corresponding numbers for ASC boosted subjects were 84% and 71%. Amongst the four sub-groups, boosted subjects showed higher prevalence of persisting seroconversion at most time points with the gap widening by 7th year, though not statistically significant (except 3rd year). Tested by Szu and also NIBSC ELISAs, 92-100% of unboosted ASC children showed persisting seroconversion at 7 years with 100% also exceeding the Szu protective threshold.To extend protection, administering a booster of Typbar TCV® to children ∼5 years after their primary dose, i.e., coinciding with school entry, may be advisable. Typbar TCV® is presently the only WHO pre-qualified Vi conjugate vaccine with reported efficacy, effectiveness, and long-term immunogenicity findings." @default.
• W3204194265 created "2021-10-11" @default.
• W3204194265 creator A5003923833 @default.
• W3204194265 creator A5013346270 @default.
• W3204194265 creator A5025422454 @default.
• W3204194265 creator A5028246884 @default.
• W3204194265 creator A5049145301 @default.
• W3204194265 creator A5064362822 @default.
• W3204194265 creator A5068632792 @default.
• W3204194265 creator A5070418935 @default.
• W3204194265 creator A5073308961 @default.
• W3204194265 creator A5085201011 @default.
• W3204194265 date "2021-10-01" @default.
• W3204194265 modified "2023-10-06" @default.
• W3204194265 title "Persisting antibody responses to Vi polysaccharide–tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination" @default.
• W3204194265 cites W1593567382 @default.
• W3204194265 cites W1968151569 @default.
• W3204194265 cites W1996188732 @default.
• W3204194265 cites W2000611496 @default.
• W3204194265 cites W2007412563 @default.
• W3204194265 cites W2018090799 @default.
• W3204194265 cites W2040929028 @default.
• W3204194265 cites W2049532298 @default.
• W3204194265 cites W2078872769 @default.
• W3204194265 cites W2147278081 @default.
• W3204194265 cites W2335972457 @default.
• W3204194265 cites W2340127586 @default.
• W3204194265 cites W2340183786 @default.
• W3204194265 cites W2593353559 @default.
• W3204194265 cites W2743014102 @default.
• W3204194265 cites W2759562520 @default.
• W3204194265 cites W2791927853 @default.
• W3204194265 cites W2810103791 @default.
• W3204194265 cites W2883928725 @default.
• W3204194265 cites W2897689962 @default.
• W3204194265 cites W2906314464 @default.
• W3204194265 cites W2989194140 @default.
• W3204194265 cites W2993293153 @default.
• W3204194265 cites W3036894342 @default.
• W3204194265 cites W3046587168 @default.
• W3204194265 cites W3125507140 @default.
• W3204194265 cites W3190947740 @default.
• W3204194265 cites W4210348703 @default.
• W3204194265 cites W4210463927 @default.
• W3204194265 doi "https://doi.org/10.1016/j.vaccine.2021.07.073" @default.
• W3204194265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34625288" @default.
• W3204194265 hasPublicationYear "2021" @default.
• W3204194265 type Work @default.
• W3204194265 sameAs 3204194265 @default.
• W3204194265 citedByCount "17" @default.
• W3204194265 countsByYear W32041942652022 @default.
• W3204194265 countsByYear W32041942652023 @default.
• W3204194265 crossrefType "journal-article" @default.
• W3204194265 hasAuthorship W3204194265A5003923833 @default.
• W3204194265 hasAuthorship W3204194265A5013346270 @default.
• W3204194265 hasAuthorship W3204194265A5025422454 @default.
• W3204194265 hasAuthorship W3204194265A5028246884 @default.
• W3204194265 hasAuthorship W3204194265A5049145301 @default.
• W3204194265 hasAuthorship W3204194265A5064362822 @default.
• W3204194265 hasAuthorship W3204194265A5068632792 @default.
• W3204194265 hasAuthorship W3204194265A5070418935 @default.
• W3204194265 hasAuthorship W3204194265A5073308961 @default.
• W3204194265 hasAuthorship W3204194265A5085201011 @default.
• W3204194265 hasBestOaLocation W32041942651 @default.
• W3204194265 hasConcept C12590561 @default.
• W3204194265 hasConcept C126322002 @default.
• W3204194265 hasConcept C159654299 @default.
• W3204194265 hasConcept C203014093 @default.
• W3204194265 hasConcept C22070199 @default.
• W3204194265 hasConcept C2777351567 @default.
• W3204194265 hasConcept C2777451964 @default.
• W3204194265 hasConcept C2779583294 @default.
• W3204194265 hasConcept C2779841045 @default.
• W3204194265 hasConcept C2780801004 @default.
• W3204194265 hasConcept C2780868878 @default.
• W3204194265 hasConcept C32611913 @default.
• W3204194265 hasConcept C71924100 @default.
• W3204194265 hasConcept C72563966 @default.
• W3204194265 hasConceptScore W3204194265C12590561 @default.
• W3204194265 hasConceptScore W3204194265C126322002 @default.
• W3204194265 hasConceptScore W3204194265C159654299 @default.
• W3204194265 hasConceptScore W3204194265C203014093 @default.
• W3204194265 hasConceptScore W3204194265C22070199 @default.
• W3204194265 hasConceptScore W3204194265C2777351567 @default.
• W3204194265 hasConceptScore W3204194265C2777451964 @default.
• W3204194265 hasConceptScore W3204194265C2779583294 @default.
• W3204194265 hasConceptScore W3204194265C2779841045 @default.
• W3204194265 hasConceptScore W3204194265C2780801004 @default.
• W3204194265 hasConceptScore W3204194265C2780868878 @default.
• W3204194265 hasConceptScore W3204194265C32611913 @default.
• W3204194265 hasConceptScore W3204194265C71924100 @default.
• W3204194265 hasConceptScore W3204194265C72563966 @default.
• W3204194265 hasIssue "45" @default.
• W3204194265 hasLocation W32041942651 @default.
• W3204194265 hasLocation W32041942652 @default.
• W3204194265 hasOpenAccess W3204194265 @default.
• W3204194265 hasPrimaryLocation W32041942651 @default.
• W3204194265 hasRelatedWork W1999104660 @default.

• next